Passage Bio Inc (PASG NASDAQ) stock market data APIs
$0.4587
-0.01(-2.2%)
as of July 3, 2025
Try our APIs with
free plan!
Passage Bio Inc Financial Data Overview
Price chart is built with
Anychart
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Prev. Close
0.4587
Open
0.4477
High
0.4741
Low
0.4274
52 wk Range
0.257-1.33
Market Cap
28 663 K
Shares Outstanding
62 148 K
EPS
-0.25
Beta
1.7
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Passage Bio Inc data using free add-ons & libraries
Get Passage Bio Inc Fundamental Data
Passage Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -58 463 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.2233
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Passage Bio Inc News
New
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative disease...
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts. Therefore, you might get the signal from the manager to steal a b...
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
Passage Bio Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment Elevated progranulin levels were sustained at up ...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
